Amgen continues investing in Ohio facility
Thousand Oaks-based Amgen is continuing its commitment to its latest facilities here in the United States after the biotech company announced a $900 million expansion of its Ohio manufacturing facility.
Announced April 25, the commitment will bring the total number of jobs created to 750 and the total investment in Central Ohio to over $1.4 billion.
Amgen, one of the largest biotechs in the world, first entered Ohio in June 2021, when it announced plans to invest in a state-of-the-art biomanufacturing facility in Central Ohio. This investment marked the company’s expansion into the Columbus Region, which enhanced its U.S.-based manufacturing capabilities and created 400 jobs upon the facility’s opening.
“Amgen has been a leading U.S.-based manufacturer of biologic medicines since 1988. Today’s investment reinforces our ongoing commitment to expanding U.S. manufacturing and ensuring patients around the world have access to our innovative medicines,” said Robert A. Bradway, chairman and CEO at Amgen.
“Ohio offers a supportive business climate, skilled workforce, and strategic location, making it an ideal choice for this next phase of our investment.”
Since passage of the Tax Cuts and Jobs Act of 2017, Amgen has invested almost $5 billion in direct capital expenditures in the United States, generating an additional downstream output to the U.S. economy of approximately $12 billion.
“Ohio has built a strong foundation for economic development, which has led companies like Amgen to see Ohio as a premier destination for growth,” said Ohio Governor Mike DeWine. “We are happy to see Amgen deepen its commitment to our state and look forward to the innovation and economic impact it will drive.”
email: [email protected]
